Plasma cytokine profiles in systemic sclerosis: Associations with autoantibody subsets and clinical manifestations

Arthritis Research and Therapy

Volumn 11, Issue 5, 2009, Pages

  Gourh, Pravitt ^a   Arnett, Frank C ^a   Assassi, Shervin ^a   Tan, Filemon K ^a   Huang, Mei ^a   Diekman, Laura ^a   Mayes, Maureen D ^a   Reveille, John D ^a   Agarwal, Sandeep K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; RNA POLYMERASE III ANTIBODY; TOPOISOMERASE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS; BLOOD; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED;

AUTOANTIBODIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 75649105070     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2821     Document Type: Article

References (32)

1. Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977, 20:975-984. 10.1002/art.1780200410, 861067.
2. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, Jin L, Arnett FC. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006, 45:694-702. 10.1093/rheumatology/kei244, 16418202.
3. Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, Pupilli C, Pizzolo G, Maggi E, Romagnani S. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997, 151:1751-1758. 1858349, 9403725.
4. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992, 35:67-72. 10.1002/art.1780350111, 1731816.
5. Molteni M, Della BS, Mascagni B, Bazzi S, Zulian C, Compasso S, Lessi M, Scorza R. Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol 1999, 116:164-168. 10.1046/j.1365-2249.1999.00842.x, 1905213, 10209521.
6. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998, 25:308-313.
7. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford) 1999, 38:612-617. 10.1093/rheumatology/38.7.612, 10461473.
8. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001, 27:140-146. 10.1016/S0923-1811(01)00128-1, 11532378.
9. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997, 24:663-665.
10. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997, 24:328-332.
11. Sato S, Hanakawa H, Hasegawa M, Nagaoka T, Hamaguchi Y, Nishijima C, Komatsu K, Hirata A, Takehara K. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 2000, 27:2838-2842.
12. Arnett FC, Reveille JD, Valdez BC. Autoantibodies to a nucleolar RNA helicase protein in patients with connective tissue diseases. Arthritis Rheum 1997, 40:1487-1492. 10.1002/art.1780401003, 9259430.
13. Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, LeRoy EC, Fritzler MJ. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996, 39:1151-1160. 10.1002/art.1780390712, 8670324.
14. Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, Fritzler MJ, Ahn C, Arnett FC. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001, 30:332-346. 10.1053/sarh.2001.20268, 11303306.
15. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007, 34:104-109.
16. Wu SP, Leng L, Feng Z, Liu N, Zhao H, McDonald C, Lee A, Arnett FC, Gregersen PK, Mayes MD, Bucala R. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006, 54:3661-3669. 10.1002/art.22179, 17075815.
17. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088.
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
19. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods 2009, 340:55-64. 10.1016/j.jim.2008.10.002, 18983846.
20. Olivier J, Johnson WD, Marshall GD. The logarithmic transformation and the geometric mean in reporting experimental IgE results: what are they and when and why to use them?. Ann Allergy Asthma Immunol 2008, 100:333-337.
21. Bombardieri S, Medsger TA, Silman AJ, Valentini G. The assessment of the patient with systemic sclerosis. Introduction. Clin Exp Rheumatol 2003, 21:S2-S4.
22. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002, 4(Suppl 3):S233-S242. 10.1186/ar565, 12110143.
23. Giacomelli R, Cipriani P, Lattanzio R, Di FM, Locanto M, Parzanese I, Passacantando A, Ciocci A, Tonietti G. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997, 108:42-46. 10.1046/j.1365-2249.1997.d01-991.x, 1904632, 9097909.
24. McGaha TL, Bona CA. Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma. Autoimmun Rev 2002, 1:174-181. 10.1016/S1568-9972(02)00027-7, 12849012.
25. Valentini G, Baroni A, Esposito K, Naclerio C, Buommino E, Farzati A, Cuomo G, Farzati B. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 2001, 21:210-217. 10.1023/A:1011024313525, 11403228.
26. Giacomelli R, Cipriani P, Fulminis A, Barattelli G, Matucci-Cerinic M, D'Alo S, Cifone G, Tonietti G. Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol 2001, 125:310-315. 10.1046/j.1365-2249.2001.01603.x, 1906121, 11529924.
27. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748. 10.1038/nature01355, 12610626.
28. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238. 10.1038/nature04753, 16648838.
29. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007, 19:652-657. 10.1016/j.coi.2007.07.020, 2288775, 17766098.
30. Murata M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Komura K, Sato S. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?. J Dermatol Sci 2008, 50:240-242. 10.1016/j.jdermsci.2008.01.001, 18329249.
31. Komura K, Fujimoto M, Hasegawa M, Ogawa F, Hara T, Muroi E, Takehara K, Sato S. Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol 2008, 35:120-125. 10.3899/jrheum.080120, 18085738.
32. Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, Fritzler MJ, Ahn C, Arnett FC. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001, 30:332-346. 10.1053/sarh.2001.20268, 11303306.